Effects of Prenatal Exposure to Second-Generation Antipsychotics on Development and Behavior Among Preschool-Aged Children: Preliminary Results From the National Pregnancy Registry for Psychiatric Medications
Conclusions: The current study is the first to examine neurobehavioral outcomes of preschool-aged children exposed prenatally to SGAs. No significant differences in overall development or behavior were detected in the exposed versus unexposed group. These preliminary findings are an important step in delineating neurodevelopmental effects of prenatal SGA exposure.PMID:38488388 | DOI:10.4088/JCP.23m14965 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - March 15, 2024 Category: Psychiatry Authors: Carol Swetlik Lee S Cohen Lauren A Kobylski Ellen T Sojka Parker C Killenberg Marlene P Freeman Adele C Viguera Source Type: research
Randomized Controlled Trial of a Brief Video Intervention to Reduce Self-Stigma of Mental Illness
Conclusions: A 2-minute social contact-based video intervention effectively yielded an immediate but not a lasting decrease in self-stigma among young individuals with ongoing mental health conditions. This is the first study to examine the effect of a video intervention on self-stigma. Future trials of self-stigma treatment interventions should explore whether combining existing interventions with brief videos enhances intervention effects.Trial Registration: NCT05878470.PMID:38451170 | DOI:10.4088/JCP.23m15034 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - March 7, 2024 Category: Psychiatry Authors: Doron Amsalem Samantha E Jankowski Philip Yanos Lawrence H Yang John C Markowitz R Tyler Rogers T Scott Stroup Lisa B Dixon Leah G Pope Source Type: research
Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial
Conclusions: No new early- or late-emerging safety concerns were observed through 25 weeks of treatment with AL 1064 mg every 2 months following initiation using ALNCD plus 30-mg oral aripiprazole. Results were consistent with known safety profiles of AL and PP and support the safety of AL 1064 mg every 2 months initiated using ALNCD plus 30-mg oral aripiprazole.Trial Registration: ClinicalTrials.gov identifier: NCT03345979.PMID:38416865 | DOI:10.4088/JCP.23m15095 (Source: Journal of Clinical Psychiatry)
Source: Journal of Clinical Psychiatry - February 28, 2024 Category: Psychiatry Authors: Leslie Citrome Sergey Yagoda Ilda Bidollari Meihua Wang Source Type: research